2020
DOI: 10.1007/s10549-020-05753-9
|View full text |Cite
|
Sign up to set email alerts
|

CELF6 modulates triple-negative breast cancer progression by regulating the stability of FBP1 mRNA

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1
1

Citation Types

5
13
0

Year Published

2020
2020
2024
2024

Publication Types

Select...
8
1

Relationship

0
9

Authors

Journals

citations
Cited by 21 publications
(18 citation statements)
references
References 34 publications
5
13
0
Order By: Relevance
“…Although CELF6 has been shown to regulate alternative splicing (Ladd et al, 2004), we find very few significant targets outside of 3 0 UTR regions, suggesting that CELF6 in the brain may be more involved with post-transcriptional regulation. UTR binding is consistent with recent work showing CELF6 is able to regulate the stability of p21 (Liu et al, 2019) and FBP (Yang et al, 2020) in cancer cells. We found very few changes to splicing in Celf6 KO mice (not shown; available at GEO: GSE160293) and few effects to TE, suggesting that CELF6 acts on its brain targets primarily to enhance mRNA degradation.…”
Section: Discussionsupporting
confidence: 91%
“…Although CELF6 has been shown to regulate alternative splicing (Ladd et al, 2004), we find very few significant targets outside of 3 0 UTR regions, suggesting that CELF6 in the brain may be more involved with post-transcriptional regulation. UTR binding is consistent with recent work showing CELF6 is able to regulate the stability of p21 (Liu et al, 2019) and FBP (Yang et al, 2020) in cancer cells. We found very few changes to splicing in Celf6 KO mice (not shown; available at GEO: GSE160293) and few effects to TE, suggesting that CELF6 acts on its brain targets primarily to enhance mRNA degradation.…”
Section: Discussionsupporting
confidence: 91%
“…Molecular heterogeneity is prominent in the TNBC subtype, and is reflected by the obvious prognostic and patient's sensitivity to chemotherapy treatment, which is the only available systemic therapy currently (1). Although TNBC patients benefit from standard chemotherapy, they still face a high recurrence rate and a high possibility of drug resistance, leaving TNBC a major challenge in the clinic (4,6). Clinical trial data show that gefitinib is well tolerated in patients with a wide range of tumor types (7).…”
Section: Introductionmentioning
confidence: 99%
“…The multifunctional p21 protein plays a significant part in cell cycle progression, cell senescence, apoptosis, and transcriptional regulation [118,119]. Moreover, the stabilization of FBP1 mRNA by CELF6 leads to suppressed cell proliferation, cell migration, and cell invasion in triple-negative breast cancer [120]. FBP1 performs a tumor suppressor function by limiting glucose uptake and glycolysis [121].…”
Section: Other Celf Membersmentioning
confidence: 99%